ATC codes:
J05AR01
EMLc
Indication
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
ICD11 code:
1C62.Z
INN
Lamivudine + zidovudine
Medicine type
Chemical agent
List type
Core
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Solid:
30 mg + 60 mg Tablet
(EMLc)
;
150 mg + 300 mg Tablet (EML)
EML status history
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the removal of lamivudine + zidovudine 150 mg + 300 mg from the EMLc to be in alignment with the recommendations of the Inter-Agency Task Team on Prevention and treatment of HIV in Pregnant Women, Mothers and their Children (1).
References:
1. Update to the optimal list of paediatric ARV formulations. IATT Meeting Report, Geneva, Switzerland, 11-12 September 2013 Geneva: World Health Organization; 2013. Available from: http://apps.who.int/medicinedocs/documents/s21435en/s21435en.pdf.